• PDF: Delivered by email usually within 12 to 48 UK business hours.

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

  • Publication Date:October 2013
  • Publisher:GBI Research
  • Product Type: Report
  • Pages:81
  • ISBN:1902029

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

Summary

GBI Research has released its research, “Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period.

Scope

- Disease overview along with treatment algorithms and treatment usage patterns
- Market size and forecast for the macular degeneration market in APAC from 2012 to 2019
- Major marketed products in the APAC along with a heat map
- In-depth analysis of pipeline along with clinical trial failure analysis
- Key drivers and restraints that have had a significant impact on the market
- Key licensing and co-development agreements in the macular degeneration market

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Macular Degeneration Asia-Pacific Market to 2019 - Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 11
2.3.1 Disease Initiation 12
2.3.2 Disease Propagation 12
2.4 Classification 14
2.4.1 Early AMD 14
2.4.2 Intermediate AMD 14
2.4.3 Advanced AMD 15
2.5 Co-morbidities and Complications 16
2.6 Diagnosis 17
2.6.1 History 17
2.6.2 Examination 17
2.6.3 Diagnostic Tests 18
2.7 Epidemiology 20
2.8 Prognosis and Disease Staging 22
2.9 Treatment Options 22
2.9.1 Pharmacological 22
2.9.2 Treatment Algorithms and Prescribing Habits 24
2.9.3 Non-pharmacological Care 26
3 Macular Degeneration Asia-Pacific Market to 2019 - Marketed Products 28
3.1 Therapeutic Landscape 29
3.1.1 Lucentis (ranibizumab) - Novartis AG/Roche (Genentech) 29
3.1.2 Eylea (aflibercept) - Regeneron Pharmaceuticals/Bayer Healthcare 30
3.1.3 Avastin (bevacizumab) - Genentech (Roche) 32
3.1.4 Macugen (pegaptanib sodium) - Valeant Pharmaceuticals/Pfizer 32
3.1.5 Visudyne (verteporfin injection) - Novartis AG 33
3.1.6 Triamcinolone Acetonide 34
3.2 Comparative Efficacy and Safety 35
4 Macular Degeneration Asia-Pacific Market to 2019 - Pipeline for Disease 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 43
4.4.1 Failure Rate 43
4.4.2 Clinical Trial Duration 44
4.4.3 Clinical Trial Size 45
4.5 Promising Drug Candidates in the Pipeline 46
4.5.1 MC-1101 - MacuCLEAR, Inc. 46
4.5.2 KH902 (Fumintide) - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 46
5 Macular Degeneration Asia-Pacific Market to 2019 - Market Forecast to 2019 48
5.1 Geographical Markets 48
5.1.1 APAC Market 48
5.1.2 Australia 50
5.1.3 China 52
5.1.4 India 54
5.1.5 Japan 56
5.2 Drivers and Barriers for the Disease Market 58
5.2.1 Drivers 58
5.2.2 Barriers 59
6 Macular Degeneration Asia-Pacific Market to 2019 - Deals and Strategic Consolidations 60
6.1 Deals Analysis 60
6.2 Major Co-development Deals 62
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR 62
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners 63
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD 63
6.2.4 Alcon Enters into Collaboration with AstraZeneca 63
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429 63
6.3 Major Licensing Deals 64
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy 65
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners 65
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma 65
6.3.4 Lpath Enters into Licensing Agreement with Pfizer 65
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science 66
7 Macular Degeneration Asia-Pacific Market to 2019 - Appendix 67
7.1 All Pipeline Drugs by Phase 67
7.1.1 Discovery 67
7.1.2 Preclinical 68
7.1.3 IND-filed and Phase 0 69
7.1.4 Phase I 69
7.1.5 Phase II 70
7.1.6 Phase III 70
7.1.7 Undisclosed 71
7.2 Market Forecasts to 2019 71
7.2.1 Asia-Pacific 71
7.2.2 Australia 71
7.2.3 China 72
7.2.4 India 72
7.2.5 Japan 72
7.3 Market Definitions 73
7.4 Abbreviations 73
7.5 References 75
7.6 Research Methodology 77
7.6.1 Coverage 77
7.6.2 Secondary Research 77
7.6.3 Primary Research 77
7.6.4 Therapeutic Landscape 78
7.6.5 Geographical Landscape 81
7.6.6 Pipeline Analysis 81
7.7 Expert Panel Validation 81
7.8 Contact Us 81
7.9 Disclaimer 81



List of Tables


Table 1: Macular Degeneration Market, Classification of AMD 14
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD 25
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD 25
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013 67
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 68
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 69
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013 69
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013 70
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013 70
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 71
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012-2019 71
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012-2019 71
Table 13: Macular Degeneration Market, China, Market Forecast, 2012-2019 72
Table 14: Macular Degeneration Market, India, Market Forecast, 2012-2019 72
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012-2019 72



List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD 13
Figure 2: Macular Degeneration Market, Types of Dry AMD 15
Figure 3: Macular Degeneration Market, Classification of AMD 16
Figure 4: Macular Degeneration Market, Amsler Grid Test 18
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012-2019 21
Figure 6: Macular Degeneration Market, Photodynamic Therapy 23
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage 24
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images 26
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012 28
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006-2012 29
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011-2012 31
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005-2012 34
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products 35
Figure 14: Macular Degeneration Market, Global, Overall Pipeline, 2013 38
Figure 15: Macular Degeneration Market, Global, Pipeline Analysis by Molecule Type, 2013 40
Figure 16: Macular Degeneration Market, Global, Pipeline Analysis by Mechanism of Action, 2013 42
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013 43
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013 44
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013 45
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012-2019 49
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012-2019 51
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012-2019 53
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012-2019 55
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012-2019 57
Figure 25: Macular Degeneration Market, Global, Deals, 2007-2013 61
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007-2013 62
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007-2013 64
Figure 28: GBI Research Market Forecasting Model 80
+44 20 8816 8548

Ask a question about Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

Enter the characters you see in the picture below
Captcha